Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study

Young, J; Scherrer, A U; Günthard, Hf; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, Ca; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, Hc; Swiss HIV Cohort Study, (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 299-307. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00885.x

Full text not available from this repository. (Request a copy)

Darunavir was designed for activity against HIV resistant to other protease inhibitors (PIs). We assessed the efficacy, tolerability and risk factors for virological failure of darunavir for treatment-experienced patients seen in clinical practice.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Fux, Christoph Andreas

ISSN:

1464-2662

Publisher:

Blackwell Science

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:13

Last Modified:

17 Mar 2015 19:15

Publisher DOI:

10.1111/j.1468-1293.2010.00885.x

PubMed ID:

20955357

Web of Science ID:

000289113400005

URI:

https://boris.unibe.ch/id/eprint/2711 (FactScience: 205579)

Actions (login required)

Edit item Edit item
Provide Feedback